Insurers cut back GLP-1 coverage as demand soars: Found study

As demand surges for GLP-1 therapies, insurers are pulling back on coverage, according to new data from obesity care provider Found. | Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.

As the market for new weight loss drugs soars, people with diabetes pay the price

Health Plan News Q1 2023

GLP-1 Receptor Agonist Shortage: Challenges and Solutions in Type

Why Won't Your Company Pay for Weight-Loss Drugs Like Wegovy

The Employer's Guide Blog for Overseeing PBMs

Focus: US diabetes patients face delays as insurers tighten

Designing fiscally viable coverage of GLP-1 weight-loss drugs

Blog – Centrum Pharmacy - Centrum Pharmacy

Denmark's largest health insurer drops weight-loss drug coverage

How GLP-1 agonist drugs could change healthcare demand